Background and Objectives

Background
• Psoriatic arthritis (PsA) is an inflammatory peripheral and/or axial arthritis associated with psoriasis, usually seronegative for rheumatoid factors 1
• Patients with PsA also have debilitating skin disease, and nearly half may also have a spinal disease. 2 PsA is estimated to affect 2.0% to 3.0% of the general population 3
• To date, few studies have examined treatment persistence of subcutaneous biologics in a real-world setting in Europe, specifically in Germany
Objectives
• To examine persistence on therapy over 12 months for PsA patients who were newly treated with subcutaneous biologics
• To assess if there are differences in treatment persistence between patients with and without prior DMARD experience
Methods
• This is a retrospective cohort study using data from the IMS Disease Analyzer-Germany database from January 
Inclusion criteria
• At least 18 years of age on index date
• At least one prescription for a subcutaneous biologic agent used in the treatment of PsA during the sample selection window -Subcutaneous biologics for PsA:
• Etanercept
• Adalimumab
• Golimumab
• At least one confirmed ICD-10 diagnosis code for PsA during the 12 months prior to the index date (preindex period), on index date, or during the 12 months following the index date (postindex period)
• Continuous observation in the Electronic Medical Record (EMR) 12 months prior to, on index date, and 12 months following the index date. Continuous observation in Disease Analyzer will be determined by the presence of at least one physician visit for any reason within the first 6 months and last 6 months in the preindex period, and separately in the postindex period
Exclusion criteria
• At least one prescription for a subcutaneous or IV biologic during the preindex period
• Diagnosis for more than one rheumatoid disease (RA, AS, or PsA) at any time during a patient's observation period (pre-or postindex)
• Diagnosis for other conditions (eg, Crohn's disease, ulcerative colitis, and other inflammatory bowel disease) treated with subcutaneous biologics identified at any time during a patient's observation period (pre-or postindex)
Operational definitions
• Treatment persistence: Persistence with index subcutaneous biologic agent was defined as time (in consecutive days) from treatment initiation until treatment discontinuation -Studies that evaluated persistence with an index subcutaneous biologic agent have defined discontinuation based on varied gaps, including 30, 60, and 90 days 4
• Discontinuation was defined as the first day of a period of at least 60 consecutive days (grace period) in which no drug supply for the index subcutaneous biologic agent was detected -A sensitivity analysis was performed using a 30-day and 90-day consecutive gap
Stratification
• Patients were further stratified as DMARD-naïve or -experienced groups -DMARD-naïve patients were not prescribed any DMARD in the preindex period -DMARD-experienced patients were defined as those who were prescribed at least one DMARD in the preindex period
• DMARDs: methotrexate, azathioprine, hydroxycholorquine, sulfasalazine, and leflunomide
Statistical analyses
• Descriptive statistics will be presented for demographic and baseline characteristics to characterize all patients -For categorical measures, the total number and percentage of patients for each characteristic were described. For continuous measures for demographic and clinical characteristics, mean and standard deviation (SD) were described
• Bivariate descriptive statistics were conducted -Statistical significant in differences in the characteristics of DMARD-naïve and -experienced patients were ascertained using Chi-square tests for categorical variables and Wilcoxon rank-sum test for continuous variables -A P-value <0.05 was considered statistically significant
• A Kaplan-Meier analysis was used to assess time to discontinuation of all subcutaneous biologic therapies -The proportion of patients in the sample who remained persistent with their index subcutaneous biologics following the index date throughout the follow-up period was estimated -Patients were censored when they discontinued treatment or at the end of the observation period
• A log-rank test was used to assess statistical differences between DMARD-naïve and -experienced patients • The baseline demographic characteristics for overall PsA patients are reported in Table 1 • Overall, the mean age was 49.4 years (SD=10.6), and the distribution of male (49.7%) and female (50.3%) patients was similar. Private medical insurance (74.6%) was the most frequent payer type • The baseline clinical characteristics for PsA patients are reported in Table 2 . A minority of patients had the identified comorbidities and rheumatoid disease-related symptoms of interest
• Of all comorbidities evaluated, psoriasis was the most common, affecting 42.6% of all PsA patients at baseline
• Inflammatory back pain was the most common rheumatoid disease-related symptom, and was present in 5.1% of the overall population • A sensitivity analysis was performed using a 30-day and 90-day consecutive gap ( Table 3) • The overall persistence rate increased as a more generous grace period (90 days) was given • The Kaplan-Meier analysis (Figure 3 ) also showed that the discontinuation pattern between DMARD-naïve and -experienced patients was comparable (P=0.7188) • Results remained consistent in the multivariate analysis ( Figure 4) 
Conclusions
• A total of 197 biologic-naïve PsA patients were selected, 122 (61.9%) with use of DMARDs in the preindex period
• In the overall PsA population, the persistence rate with the index subcutaneous biologic was 54.3%, with similar results among those with and without DMARDs use (53% vs 56%, respectively)
• Multivariate analysis did not identify any significant predictors for persistence, including DMARD use (OR: 1.05; 95% CI: 0.53-2.07) and psoriasis (OR: 1.07; 95% CI: 0.56-2.03)
Limitations
• Retrospective database research may include coding errors and undercoding contained in records
• Patients treated with biologic agents in private office settings were not captured in this analysis
• The measures of persistence were determined by the presence of a written prescription, with the assumption that the prescription was administered as ordered
• The cross-sectional research design does not support causal associations
• Lastly, the sample sizes of the overall cohort and comparison groups were small
